Natera, Inc. $NTRA Stock: Westpac Banking Corp Reduces Position

Westpac Banking Corp lessened its position in Natera, Inc. (NASDAQ:NTRA – Free Report) by 30.7% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 7,081 shares of the medical research company’s stock after selling 3,133 shares during the quarter. Westpac Banking Corp’s holdings in Natera were worth $2,927,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of NTRA. Trust Co. of Vermont acquired a new stake in shares of Natera during the 2nd quarter worth about $26,000. Elevation Wealth Partners LLC acquired a new stake in shares of Natera in the second quarter valued at $30,000. Continuum Advisory LLC purchased a new position in shares of Natera in the 2nd quarter valued at about $33,000. Rakuten Securities Inc. acquired a new position in Natera during the 2nd quarter worth approximately $35,000. Finally, Transamerica Financial Advisors LLC purchased a new position in Natera in the second quarter valued at $39,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently weighed in on NTRA. TD Cowen boosted their price target on shares of Natera from $340.00 to $480.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. Piper Sandler reissued an “overweight” rating and set a $363.50 price target on shares of Natera in a report on Friday, November 6th. Leerink Partners set a $330.00 price target on shares of Natera in a research note on Friday, August 7th. Barclays lifted their price objective on Natera from $340.00 to $475.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Finally, Zacks Research downgraded shares of Natera from a “hold” rating to a “strong sell” rating in a report on Friday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $394.31.

View Our Latest Stock Analysis on NTRA

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $289.92 on Friday. The business’s 50-day simple moving average is $376.63 and its 200 day simple moving average is $272.74. The company has a market cap of $42.04 billion, a P/E ratio of -254.32 and a beta of 1.55. Natera, Inc. has a one year low of $181.00 and a one year high of $437.41.

Natera (NASDAQ:NTRA – Get Free Report) last issued its earnings results on Thursday, November 5th. The medical research company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.14). The firm had revenue of $793.98 million during the quarter, compared to analyst estimates of $707.54 million. Natera had a negative return on equity of 8.61% and a negative net margin of 5.66%. Natera’s revenue was up 34.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.64) EPS. Analysts predict that Natera, Inc. will post -1.25 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Michael Brophy sold 1,906 shares of the stock in a transaction on Friday, October 30th. The stock was sold at an average price of $425.55, for a total transaction of $811,098.30. Following the completion of the sale, the chief financial officer owned 46,574 shares in the company, valued at approximately $19,819,565.70. This represents a 3.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 15,160 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $326.89, for a total transaction of $4,955,652.40. Following the completion of the sale, the insider directly owned 110,859 shares of the company’s stock, valued at $36,238,698.51. This trade represents a 12.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 47,056 shares of company stock valued at $17,760,989 over the last three months. Company insiders own 5.05% of the company’s stock.

About Natera

(Free Report)

Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.

See Also

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.